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Intravenous iodinated contrast media are commonly used with CT to evaluate disease and to determine treatment response.
The risk of acute kidney injury (AKI) developing in patients with reduced kidney function following exposure to intravenous
iodinated contrast media has been overstated. This is due primarily to historic lack of control groups sufficient to separate
contrast-induced AKI (CI-AKI; ie, AKI caused by contrast media administration) from contrast-associated AKI (CA-AKI;
ie, AKI coincident to contrast media administration). Although the true risk of CI-AKI remains uncertain for patients with
severe kidney disease, prophylaxis with intravenous normal saline is indicated for patients who have AKI or an estimated glomerular
filtration rate less than 30 mL/min/1.73 m2 who are not undergoing maintenance dialysis. In individual high-risk circumstances, prophylaxis may be considered in patients with an estimated glomerular filtration rate of 30–44 mL/min/1.73 m2 at the discretion of the ordering clinician.
This article is a simultaneous joint publication in Radiology and Kidney Medicine. The articles are identical except for stylistic
changes in keeping with each journal’s style. Either version may be used in citing this article.
© 2020 RSNA and the National Kidney Foundation published by Elsevier Inc. This is an open access article under the CC BY NC-ND license.

Introduction and Background

I

ntravenous iodinated contrast media are commonly
used with CT to evaluate disease and to determine
treatment response. Although patients have benefited
from their use, iodinated contrast media historically
have been denied or delayed in patients with reduced
kidney function due to the perceived risks of contrastinduced acute kidney injury (CI-AKI) (1,2). This is
important because denying patients diagnostic testing
that is indicated in a timely fashion creates potential for
indirect harm related to delayed diagnosis and misdiagnosis (3).
Because of the critical role contrast media play in
modern medical imaging, clinicians and diagnostic radiologists are routinely charged with balancing the potential risks of contrast media administration with diagnostic benefits (1,2). However, clinical decision making
in patients potentially at risk for acute kidney injury
(AKI) is often fraught with confusion, uncertainty, and
heterogeneity. This is due in part to shifting perceptions
regarding the true risks of modern contrast media (1–6),
improvements in scientific methodology used to study
these adverse events (7–13), incomplete penetrance of
new knowledge into scientific practice (14), latent bias

related to historical precedent (1,2), uncertainty regarding the interpretation of recently conducted well-controlled observational studies (4–6), and differences in
recommendations across radiology and medical subspecialties (15–18).
In this document, joint statements are made by a
multidisciplinary group of radiologists (M.D., R.M.,
J.W., J.D., C.W.) and nephrologists (M.P., J.Y., R.R.,
D.F.). These statements are endorsed by the American
College of Radiology, or ACR, and the National Kidney Foundation, or NKF, to improve and standardize
the care of patients with impaired kidney function who
have indication(s) to receive intravenous iodinated contrast media. These opinions and recommendations are
only applicable to intravenous (eg, contrast material–
enhanced CT) as opposed to intra-arterial (eg, coronary
artery angiography) contrast media administration,
because intra-arterial administration has unique considerations that do not apply to the intravenous route
of administration (eg, requirement for arterial access,
atheroembolic complications, population-specific risk
factors for AKI) (19).
It is important to recognize that in clinical practice,
a multitude of factors are used to determine whether
intravenous contrast media should be administered (eg,
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Abbreviations
AKI = acute kidney injury, CA-AKI = contrast-associated AKI, CI-AKI =
contrast-induced AKI, CKD = chronic kidney disease, eGFR = estimated
glomerular filtration rate, IOCM = iso-osmolality contrast media, LOCM
= low-osmolality contrast media, PC-AKI = postcontrast AKI

Summary
These statements are endorsed by the American College of Radiology
and the National Kidney Foundation to improve and standardize the care of patients with impaired kidney function who have
indication(s) to receive intravenous iodinated contrast media.

probability and necessity of an accurate diagnosis, alternative methods of diagnosis, risks of misdiagnosis, expectations
about kidney functional recovery, allergic-like reaction risk).
Decisions are rarely based on a single consideration (eg, risk
of an adverse event specifically related to kidney impairment).
Consequently, these statements should be considered in the
context of the entire clinical scenario.

Nomenclature and Definitions
AKI (Fig 1) occurring within 48 hours of intravenous contrast media administration and after the exclusion of other
nephrotoxic factors has been termed contrast-induced nephropathy (2). This definition is problematic because in most
cases, “exclusion of other nephrotoxic factors” is not feasible
or reliable (2). Consequently, many cases of AKI that are coincident with but causally unrelated to intravenous contrast
media administration have been incorrectly attributed as
contrast induced, thereby overstating the risks of intravenous
contrast media administration (1–13,15). The vast majority
of studies on this topic have not included a control group
of similar patients who were not exposed to contrast media,
making it impossible to separate causal from coincident AKI
(20). However, recent (2013–present) large, well-controlled,
observational series have shown that a substantial proportion
of AKI that occurs after intravenous contrast media administration is not attributable to contrast media (7,8,10,11,13).
Therefore, in 2015, the ACR Committee on Drugs and
Contrast Media adopted new terms that were intended to
disentangle the implicit causal relationship between contrast
media and AKI (15). The following terms are endorsed in
these consensus statements:
Contrast-associated acute kidney injury (CA-AKI): Any
AKI occurring within 48 hours after the administration of
contrast media. The term postcontrast acute kidney injury (PCAKI) is synonymous with CA-AKI and appears in radiology
guidelines (15). Both terms imply correlative diagnosis. Neither term implies a causal relationship between contrast medium administration and an AKI event. Related AKI events
that occur in clinical care and events documented in study
protocols that lack a control cohort are best termed CA-AKI
or PC-AKI.
Contrast-induced acute kidney injury (CI-AKI): CI-AKI
is the subset of CA-AKI that can be causally linked to contrast
media administration. CI-AKI implies a causal relationship
between intravenous contrast media and the development of
Radiology: Volume 294: Number 3—March 2020 n radiology.rsna.org

Image shows Kidney Disease Improving Global Outcomes (KDIGO) staging criteria for acute kidney injury (AKI) and chronic kidney disease (CKD). Urine
output criteria for AKI staging were not included. ACR = albumin creatinine ratio,
AER = albumin excretion rate, Cr = creatinine, GFR = glomerular filtration rate.

AKI (ie, contrast induced). Use of the term CI-AKI (formerly
termed contrast-induced nephropathy) in clinical practice
can be misleading because of the large fraction of false-positive events (ie, AKI related to concurrent nephrotoxic exposure or insults in proximity to the time of contrast media
administration). Only studies with a well-matched control
group can establish a potential causal relationship.

Diagnosis of CI-AKI and Chronic Kidney Disease
Updated Kidney Disease
Kidney Disease Improving Global Outcomes, or KDIGO,
criteria are recommended for the diagnosis of CA-AKI and,
when feasible, in the context of a controlled study, for the
diagnosis of CI-AKI (17,21,22). KDIGO criteria are endorsed by the NKF Kidney Disease Outcomes Quality Initiative as a consensus definition for epidemiologic and clinical research applications (17). Although serum creatinine is
an imperfect biomarker for AKI, it remains the most common and practical clinical method of diagnosing AKI. Reduced urine output is another criterion to diagnose AKI by
using KDIGO criteria, but change in urine output can be
661
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more challenging to assess in retrospective studies because it
is not always rigorously documented (7,8,10,11,13).
KDIGO criteria are recommended for the diagnosis of
chronic kidney disease (CKD) (Fig 1) and are endorsed by
NKF Kidney Disease Outcomes Quality Initiative (23,24).
Although the estimated glomerular filtration rate (eGFR) has
intrinsic error due to reliance on serum creatinine and lack
of validation in patients with AKI, low muscle mass, or in
patients treated with dialysis (23–25), eGFR is the most accurate and least biased method commonly available in clinical
practice to stratify KDIGO CKD stage by using glomerular
filtration rate (“G” based on eGFR) (Fig 1).
Because of the historical conflation of CA-AKI and CIAKI, many relevant published studies that have used CAAKI as an outcome have inaccurately labeled it CI-AKI (ie,
contrast-induced nephropathy) (2,20). Therefore, while there
is ample evidence for the existence of CA-AKI, the evidence
base for CI-AKI is sparse (2,3,13,20). Several topics in this
document are addressed from the perspective of generic CAAKI due to an insufficient evidence base for CI-AKI. Where
feasible, specific commentary about CI-AKI is made. These
statements enable providers to make judgments in specific
circumstances.

Key Questions and Joint NKF-ACR Statements
What Is the Risk of CA-AKI and CI-AKI in Patients Who
Have eGFR Less Than 30, 30–44, 45–59, and Greater Than
or Equal to 60 mL/Min/1.73 m2 Undergoing Contrastenhanced CT?

What Other Major Patient-related Factors Increase the Risk
of CA-AKI or CI-AKI?
Contrast-associated AKI.—Multiple patient-related risk
factors have been associated with CA-AKI (15–17,26). The
primary risk factor is eGFR, with some studies finding an
additive risk of CA-AKI from diabetes mellitus (15–17,26).
Additional risk factors include nephrotoxic agents and exposures, hypotension, hypovolemia, albuminuria, and impaired
kidney perfusion (eg, congestive heart failure [27]). Although
multiple myeloma has long been considered a risk factor
for CA-AKI, this is not supported by more recent literature
(28–30).
Contrast-induced AKI.—Few studies have linked patient-related risk factors with CI-AKI. In studies that found evidence
of CI-AKI, the primary risk factor was eGFR (7–11,13,15).
No other putative risk factors that increase CI-AKI risk beyond eGFR alone have been confirmed in well-controlled
studies of intravenous media.
Are There Clinically Relevant Differences in CA-AKI and
CI-AKI Risk for Patients with Reduced Kidney Function with
Intravenous Iodinated Low-Osmolality Contrast Media
Compared with Intravenous Iodinated Iso-Osmolality
Contrast Media?

Contrast-associated AKI.—The risk of CA-AKI (coincident
AKI of any cause) increases with each stepwise increase in
CKD stage (7–11,13,15). Using stage I KDIGO serum creatinine criteria, the risk of CA-AKI is approximately 5% at
eGFR greater than or equal to 60, 10% at eGFR of 45–59,
15% at eGFR of 30–44, and 30% at eGFR less than 30 mL/
min/1.73 m2. This risk is much higher than the risk of CIAKI because it includes any AKI coincident to contrast media
administration, regardless of contrast media exposure.

Contrast-associated AKI.—There are no confirmed clinically
relevant differences in risk of CA-AKI between low-osmolality contrast media (LOCM) and iso-osmolarity contrast media (IOCM) for intravenous applications (31). Indirect evidence suggests that the LOCM iohexol may have a higher risk
compared with other LOCM, but that potential risk difference has not been confirmed (31). Randomized studies comparing LOCM and IOCM primarily analyzed intra-arterial
administrations and have mixed results (31). Based on results
of a 2015 systematic review and meta-analysis, any difference
in risk of CA-AKI between LOCM and IOCM is not likely
to be clinically meaningful (31).

Contrast-induced AKI.—The risk of CI-AKI is substantially less
than the risk of CA-AKI, but the actual risk remains uncertain
in patients with severe kidney disease. Several large controlled
observational studies have shown no evidence of CI-AKI regardless of CKD stage (10,11,13), whereas others found evidence of CI-AKI only in patients with severely reduced kidney
function (7,8,13). In such studies, the risk of CI-AKI has been
estimated to be near 0% at eGFR greater than or equal to 45,
0%–2% at eGFR of 30–44, and 0%–17% at eGFR less than
30 mL/min/1.73 m2. These studies (1–8,10,11,13) are underpowered to establish risk in patients with severe kidney
disease, differ in their conclusions about risk in patients with
eGFR less than 30 mL/min/1.73 m2 (estimated CI-AKI risk
range, 0%–17%), and are observational in design (ie, only
known confounders can be addressed). There are no randomized trials differentiating CA-AKI from CI-AKI in patients
with eGFR less than 30 mL/min/1.73 m2.

Contrast-induced AKI.—No studies have directly compared
risk of CI-AKI between LOCM and IOCM. However, randomized trials comparing contrast media using CA-AKI as
an outcome (31) inform the risk of CI-AKI because, other
than the contrast media exposure, the groups are balanced
(ie, the outcome is a combination of CA-AKI unrelated to
contrast media and CI-AKI, with the primary difference being the CI-AKI fraction). There is thought to be no clinically
relevant difference in risk of CI-AKI between LOCM and
IOCM (31).
Despite the acronym, LOCM are hyperosmolar (approximately 600 mOsm/kg) relative to both IOCM (approximately 290 mOsm/kg) and serum (approximately 290
mOsm/kg) (15). However, the dimeric structure of IOCM
renders them more viscous than LOCM (15). Most modern
iodinated contrast media are classified as LOCM (15). Highosmolality iodinated contrast media have higher osmolality
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than do LOCM and IOCM, but high-osmolality iodinated
contrast media has been replaced by LOCM and IOCM for
intravenous administration in modern clinical practice (15).
Which Patients Should Undergo Prophylaxis to Prevent
AKI prior to Intravenous Iodinated Contrast Media
Administration?
Prophylaxis is indicated for patients who have AKI or an eGFR
less than 30 mL/min/1.73 m2 and are not undergoing maintenance dialysis (15,26,32,33). However, the evidence supporting this statement is based on data for the general prevention of CA-AKI rather than CI-AKI specifically. The risks of
prophylaxis (eg, heart failure, other hypervolemic conditions)
should be considered before initiation (34,35). Prophylaxis
is not indicated for the general population of patients with
stable eGFR greater than or equal to 30 mL/min/1.73 m2
(35), for patients undergoing chronic dialysis, or for patients
at risk for heart failure (34,35). This eGFR threshold should
not be adjusted solely based on concomitant diabetes mellitus (7–11,13,15,36). In a 1:1 propensity-matched observational study of 1112 patients with stable eGFR of 30–44 mL/
min/1.73 m2, diabetes mellitus did not independently increase
risk of CI-AKI in patients undergoing contrast-enhanced CT
(P = .22) (31).
In individual high-risk circumstances (eg, numerous risk
factors, recent AKI, borderline eGFR), prophylaxis may be
considered in patients with eGFR of 30–44 mL/min/1.73
m2 at the discretion of the ordering clinician. If a contrastenhanced imaging study that otherwise would be preceded
by prophylaxis has an emergent indication and there is insufficient time for preprocedural prophylaxis, then postprocedural prophylaxis may be considered, but there is no evidence
to support this action.
When prophylaxis is indicated, isotonic volume expansion
with normal saline is the preferred method (15,26,32,33).
The ideal timing, volume, and rate of volume expansion is
uncertain. Typical volume expansion regimens begin 1 hour
before and continue 3–12 hours after contrast media administration, with typical doses ranging from fixed (eg, 500 mL
before and after) to weight-based volumes (1–3 mL/kg per
hour) (15,26). Longer regimens (approximately 12 hours)
have been shown to lower the risk of CA-AKI compared with
shorter regimens (15,37). However, longer intravenous protocols are generally impractical in the outpatient setting. Oral
hydration has not been well studied for patients with eGFR
less than 30 mL/min/1.73 m2 or AKI (38,39).
Although bicarbonate is likely similar to normal saline for
the prevention of CA-AKI (40), it is not preferred because
bicarbonate solutions require pharmacist compounding. Nacetylcysteine was not shown to be effective versus placebo in
a recent randomized trial of intra-arterial iodinated contrast
media administration (40) and is not recommended for intravenous contrast media exposure prophylaxis. In patients
with eGFR less than 30 mL/min/1.73 m2 or AKI, cessation of
nonessential nephrotoxic medications (eg, nonsteroidal antiinflammatory drugs) may decrease the risk of CA-AKI and is
recommended when feasible.
Radiology: Volume 294: Number 3—March 2020 n radiology.rsna.org

Should Screening Be Used to Identify Patients at Risk for
CI-AKI?
Screening based on eGFR should be used to identify patients at
potential risk of CI-AKI (15,16). Screening based on eGFR is
preferred over serum creatinine–based screening (17,23,24,41).
Ideally, serum creatinine measurements should undergo calibration traceable to isotope dilution mass spectroscopy (42).
Following accurate calibration, eGFR should be calculated
with a validated isotope dilution mass spectroscopy–traceable
equation (eg, chronic kidney disease epidemiology collaboration, Modification of Diet in Renal Disease) (42).
What patient risk factors should be used to trigger eGFR
measurement?—A variety of screening data elements have
been considered that variably affect the sensitivity and specificity of kidney function screening (15,43,44). A personal history of kidney disease (eg, CKD, remote AKI, kidney surgery,
kidney ablation, albuminuria) is the most useful element that
demonstrates a requirement for kidney function determination (15,43,44). Diabetes mellitus is an optional factor for
screening (43,44). Patient age and both treated and untreated
hypertension are of uncertain utility as independent triggers
for kidney function assessment during radiology point of care;
they are sensitive indicators and confer a large false-positive
rate to the identification of patients with eGFR less than 30
mL/min/1.73 m2.
What eGFR threshold should be used by radiologists to trigger consultation with the referring clinician prior to intravenous administration of contrast media?—Patients with AKI
or eGFR less than 30 mL/min/1.73 m2 (including nonanuric
patients undergoing maintenance dialysis [see below]) should
prompt consideration by the referring professional and radiologist to discuss the risks and benefits of contrast media administration (15,16). Because of a lack of data supporting an
additive risk of CI-AKI beyond CKD stage, the eGFR threshold does not need to be modified based on chronic diseases
such as diabetes mellitus (15,16). Acute clinical risk factors (eg,
volume depletion) without known AKI are beyond the scope
of radiology practices to determine and are left to referring clinicians to evaluate. In general, when stable, eGFR is the best
indicator of a patient’s potential risk of CI-AKI (15,16).
Should Intravenous Iodinated Contrast Media Be Withheld
in Patients with CKD Stages 4 or 5 Not Undergoing
Maintenance Hemodialysis?
Patients with CKD stages 4 or 5 (eGFRs of 15–29 mL/
min/1.73 m2 or ,15 mL/min/1.73 m2, respectively) who
are not undergoing maintenance hemodialysis are at potential risk of CI-AKI (7,8,13,15,16,26). The number needed
to harm from contrast media administration (ie, one patient
developing CI-AKI after x exposed patients) has been calculated in well-controlled observational studies to be as low as
six and as high as infinity (ie, no harm) (1,2). Patients with
CKD stages 4 or 5 have a relative rather than absolute contraindication to iodinated contrast media (15,16). If contrast
media administration is required for a life-threatening diag663
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nosis, then it should not be withheld based on kidney function (15). If intravenous iodinated contrast media administration is clinically indicated, then its use should be informed
by consideration of the potential risks and benefits as well
as alternative imaging strategies. If the decision is made to
administer iodinated contrast media in this setting, then volume expansion with normal saline is indicated if there are no
contraindications (see above).
If intravenous iodinated contrast media is administered in this
setting, then should the patient undergo dialysis in addition
to standard prophylaxis?—Because of the inherent demonstrated lack of benefit, risks, and cost, neither acute dialysis nor
continuous renal replacement therapy should be initiated or
have the schedule changed solely based on iodinated contrast
media administration, regardless of residual kidney function
(15,17,26,32,44–47).
Do Patients Undergoing Maintenance Dialysis with Residual
Kidney Function Require Different Treatment than Do Those
without Residual Kidney Function?
From an operational standpoint, patients undergoing dialysis
who make more than 1–2 cups of urine daily (approximately
100 mL) can be considered nonanuric (17). Nonanuric patients
undergoing maintenance dialysis, whether peritoneal dialysis
or hemodialysis, are at increased risk of further loss of residual
kidney function following nephrotoxic exposure(s). Although
unproven for intravenous iodinated contrast media, loss of
residual kidney function may have adverse quality-of-life and
overall survival implications. Therefore, nonanuric patients with
residual kidney function undergoing maintenance dialysis are
considered similar to patients with AKI or eGFRs less than 30
mL/min/1.73 m2 not undergoing dialysis with respect to the potential nephrotoxic risk of iodinated contrast media (ie, relative
contraindication). If loss of residual kidney function is considered clinically important, then the risks, benefits, and alternatives should be considered, and the need for the procedure
may require discussion between the referring professional and
radiologist.
Are Patients with a Single Kidney at Increased Risk for CA-AKI
or CI-AKI Beyond That Associated with Their eGFR?
Patients with a single normal or partially functioning kidney
(eg, kidney agenesis, nephrectomy, transplant) should be managed similarly to patients with normal kidney volume (eg, two
normal kidneys) (15,48). In patients with a single normal
or partially functioning kidney, clinical risk should be determined based on overall kidney function (ie, eGFR) and clinical
circumstances (ie, AKI). The presence of a solitary functioning
kidney should not influence decision making regarding the risk
of CA-AKI or CI-AKI (15,48).
If a Patient Is Determined to Be at Risk for CI-AKI, Then Should
the Dose of Iodinated Contrast Media with Contrast-enhanced
CT Be Reduced?
Although correlative data link higher doses of contrast media
to greater risk of CA-AKI following intra-arterial administra664

tion, no analogous data exist that imply a dose-ranging toxicity
for intravenous administration within the range of clinically
administered doses. Consequently, if iodinated contrast media
is administered to a patient at risk, then a conventional single
diagnostic dose should be used (ie, volume typically used for a
single diagnostic dose). Ad hoc contrast media dose reductions
as an effort to mitigate risk of CI-AKI should be avoided because this practice may produce a suboptimal or nondiagnostic
study. If lower doses of contrast media have been shown to
be sufficiently diagnostic with specific protocols, then practices should consider lowering doses in all patients imaged
with those protocols, not only patients with reduced kidney
function.
Should Any of the Above Recommendations Be Altered
in Patients Receiving Certain Nephrotoxic Medications
or Undergoing Chemotherapy, Especially If They Have
Normal Kidney Function?
In general, recommendations 1–9 should not be altered in
patients receiving nephrotoxic medications or undergoing
chemotherapy. This is especially true for patients who have
normal eGFR or mild-to-moderate reductions in eGFR because
they are not considered at risk, regardless of the drug(s)
prescribed (13,15). However, monitoring eGFR in patients
receiving nephrotoxic medications (eg, aminoglycosides) or
undergoing chemotherapy is important before, during, and
after treatment to identify incident nephrotoxicity (eg, AKI
or new eGFR ,30 mL/min/1.73 m2) (49).
Is there a role for withholding certain medications prior to
intravenous iodinated contrast media administration to
decrease the risk of kidney injury?—In patients with AKI
or eGFRs less than 30 mL/min/1.73 m2, it may be prudent
to withhold nonessential potentially nephrotoxic medications
(eg, nonsteroidal anti-inflammatory drugs, diuretics, aminoglycosides, amphotericin, platins, zoledronate, methotrexate)
if clinically feasible for 24 to 48 hours before and 48 hours
after exposure (17,21,26).
Whether to withhold renin-angiotensin-aldosterone system inhibitors, or RAASi, is controversial. Conflicting data
support increased risk for CA-AKI, no risk for CA-AKI, and
potentially less risk of CA-AKI with RAASi (50–56). Many
of these publications are small studies that include different
routes of contrast media administration (venous vs arterial),
variable definitions of CA-AKI, and inconsistent prophylactic
measures. In addition, the effect on long-term kidney function is insufficiently studied. A meta-analysis of 12 studies and
4493 patients found no difference in risk of CA-AKI (odds
ratio: 1.27; 95% confidence interval: 0.77, 2.11; P = .35)
between patients receiving and patients not receiving RAASi
(57). However, in stratified analysis, there was an increased risk
for CA-AKI (odds ratio: 2.06; 95% confidence interval: 1.62,
2.61; P , .001) for chronic RAASi users who did not withhold
the drug. This relationship was not present in patients new to
RAASi (57). Given the lack of strong evidence demonstrating
that continuing RAASi is beneficial, referring clinicians should
consider withholding RAASi in patients at risk for at least 48
radiology.rsna.org n Radiology: Volume 294: Number 3—March 2020
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Table: Summary of Major ACR-NKF Consensus Statements on Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease, with Comparison to ACR (2018) and KDIGO (2012) Guidelines for CI-AKI

Summary
1. The terms CA-AKI or PC-AKI are recommended for use in clinical practice due to the large proportion of AKI events correlated with
but not necessarily caused by contrast media administration.
a. ACR: Similar recommendation to distinguish generic PC-AKI from CI-AKI
b. KDIGO: No recommendation regarding terminology, although it is acknowledged that AKI may be caused by other things
2. CI-AKI is only feasible to diagnose in the context of a well-matched controlled study.
a. ACR: Not specifically addressed
b. KDIGO: Not specifically addressed
3. KDIGO AKI criteria are recommended for the diagnosis of AKI, and KDIGO CKD criteria are recommended for the diagnosis of CKD.
a. ACR: AKIN criteria recommended
b. KDIGO: KDIGO criteria recommended
4. The risk of CI-AKI from intravenous iodinated contrast media is lower than previously thought. Necessary contrast material–enhanced CT
without a suitable alternative should not be avoided solely on the basis of CI-AKI risk.
a. ACR: Similar recommendation
b. KDIGO: Similar recommendation
5. CI-AKI risk should be determined primarily by using CKD stage and AKI. Patients at high risk include those with recent AKI and those with
eGFR less than 30 mL/min/1.73 m2, including nonanuric patients undergoing maintenance dialysis.
a. ACR: Similar recommendation
b. KDIGO: Similar recommendation, but eGFR threshold is less than 45 mL/min/1.73 m2 instead of less than 30 mL/min/1.73 m2
6. Kidney function screening is indicated to identify patients at high risk for CI-AKI. Personal history of kidney disease (CKD, remote AKI,
kidney surgery or ablation) is the strongest risk factor indicating the need for kidney function assessment.
a. ACR: Similar recommendation, but also includes age, diabetes mellitus, and hypertension as potential risk factors to indicate kidney
function assessment
b. KDIGO: Similar recommendation, but also includes age, diabetes mellitus, hypertension, multiple myeloma, gout, and proteinuria as
potential risk factors to indicate kidney function assessment
7. Radiologist-clinician discussions about risks and benefits of contrast-enhanced imaging can be helpful in patients at high risk for CI-AKI.
a. ACR: Not specifically addressed
b. KDIGO: Not specifically addressed
8. There are no clinically relevant differences in CI-AKI risk between iso-osmolality and low-osmolality iodinated contrast media.
a. ACR: Similar recommendation
b. KDIGO: Similar recommendation
9. Prophylaxis with intravenous normal saline is indicated for patients not undergoing dialysis who have eGFR less than 30 mL/min/1.73 m2 or
AKI. In individual high-risk circumstances, prophylaxis may be considered in patients with eGFR of 30–44 mL/min/1.73 m2 at the discretion of the ordering clinician.
a. ACR: Prophylaxis with normal saline recommended for patients not undergoing dialysis with eGFR less than 30 mL/min/1.73 m2; no
exception for patients with eGFR of 30–44 mL/min/1.73 m2 and multiple risk factors
b. KDIGO: Prophylaxis with normal saline or sodium bicarbonate recommended for patients not undergoing dialysis with eGFR less
than 45 mL/min/1.73 m2; prophylaxis may include N-acetylcysteine
10. Prophylaxis is not indicated for patients with stable eGFR greater than or equal to 45 mL/min/1.73 m2.
a. ACR: Prophylaxis not recommended for patients with eGFR greater than or equal to 30 mL/min/1.73 m2
b. KDIGO: Necessity of prophylaxis is ambiguous for patients with eGFR of 45–59 mL/min/1.73 m2
11. Kidney replacement therapy should not be initiated or have the schedule adjusted solely on the basis of contrast media administration.
a. ACR: Similar recommendation
b. KDIGO: Similar recommendation
12. The presence of a solitary kidney should not independently influence decision making regarding the risk of CI-AKI.
a. ACR: Not specifically addressed
b. KDIGO: Not specifically addressed
13. In patients at high risk of CI-AKI, ad hoc lowering of contrast media dose below a known diagnostic threshold should be avoided.
Rather, the minimum routine clinical diagnostic dose should be used.
a. ACR: Not specifically addressed
b. KDIGO: Contrast media dose reduction recommended
14. When feasible, nephrotoxic medications should be withheld by the referring clinician in patients at high risk.
a. ACR: Not specifically addressed
b. KDIGO: Similar recommendation
Table (continues)
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Table (continued): Summary of Major ACR-NKF Consensus Statements on Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease, with Comparison to ACR (2018) and KDIGO (2012) Guidelines for CI-AKI

15. Data on risk of CI-AKI in pediatric patients is extrapolated from data in adult patients. Pediatric-specific research in this area is a major
unmet need.
a. ACR: Similar recommendation
b. KDIGO: Not specifically addressed
Note.—ACR = American College of Radiology, AKI = acute kidney injury, AKIN = Acute Kidney Injury Network, CA-AKI = contrastassociated AKI, CI-AKI = contrast-induced AKI, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, KDIGO =
Kidney Disease Improving Global Outcomes, NKF = National Kidney Foundation, PC-AKI = postcontrast acute AKI.
Source.—References 15, 17, 21.

hours before elective contrast-enhanced CT to avoid the potential for hypotension and hyperkalemia should CA-AKI develop. RAASi may be restarted if CA-AKI does not occur or
following the return of kidney function to baseline.
Metformin does not increase risk of CA-AKI. If CI-AKI
develops in a patient receiving metformin, then the risk of
lactic acidosis is increased. Therefore, metformin should be
withheld in patients with AKI or eGFR less than 30 mL/
min/1.73 m2, consistent with U.S. Food and Drug Administration recommendations to generally avoid metformin at
this level of kidney function. Although the FDA also recommends withholding metformin prior to iodinated contrast
media exposure for eGFR 30–59 mL/min/1.73 m2 (58),
decision making should be individualized by referring clinicians at this eGFR level because the risk of CI-AKI is sufficiently low.
If CA-AKI develops, then nonessential nephrotoxic medications should continue to be withheld until kidney function has
recovered (17,21,26). In some cases, withholding a nephrotoxic
drug or the delay of an indicated imaging examination while
waiting for an administered nephrotoxic drug to be eliminated
may carry more risk than the potential risk of CI-AKI. Therefore,
decisions regarding the suspension of medications should be
individualized by referring and other treating providers.
Should Any of the Above Be Altered in Infants and Children?
Kidney function measurement in infants and children is optimally evaluated by the Bedside Schwartz equation rather than
by eGFR equations developed and validated in adults (59–61).
In general, the aforementioned recommendations should not
be altered for infants and children, but there are minimal data
assessing risk of CI-AKI in this population (62). Recommendations for this population are largely based on extrapolated adult
data (15). The risk of CI-AKI from intravenous contrast media in infants and children is a pressing research need.

Summary
The putative risk of administering modern intravenous iodinated contrast media in patients with reduced kidney function
has been overstated. This is primarily because of the conflation
of contrast-associated acute kidney injury (CA-AKI) with contrast-induced acute kidney injury (CI-AKI) in uncontrolled
studies. Although the true risk of CI-AKI remains unknown,
prophylaxis with intravenous normal saline is indicated for
patients without contraindication (eg, heart failure) who have
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acute kidney injury (AKI) or an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2 who are not
undergoing maintenance dialysis. In individual high-risk circumstances, prophylaxis may be considered in patients with
an eGFR of 30–44 mL/min/1.73 m2 at the discretion of the
ordering clinician. The presence of a solitary kidney should
not independently influence decision making regarding the
risk of CI-AKI. Ad hoc lowering of contrast media dose below
a known diagnostic threshold should be avoided due to the
risk of lowering diagnostic accuracy. When feasible, nephrotoxic medications should be withheld by the referring clinician
in patients at high risk. However, renal replacement therapy
should not be initiated or altered solely based on contrast media administration. Prospective controlled data are needed in
adult and pediatric populations to clarify the risk of CI-AKI. A
summary of these recommendations with comparison to existing guidelines is provided in the Table.
Author contributions: Guarantor of integrity of entire study, M.S.D.; study con-

cepts/study design or data acquisition or data analysis/interpretation, all authors;
manuscript drafting or manuscript revision for important intellectual content, all
authors; approval of final version of submitted manuscript, all authors; agrees to
ensure any questions related to the work are appropriately resolved, all authors;
literature research, all authors; clinical studies, M.A.P., R.A.R.; and manuscript
editing, all authors

Disclosures of Conflicts of Interest: M.S.D. Activities related to the present article:

disclosed no relevant relationships. Activities not related to the present article: receives royalties from UpToDate and Wolters Kluwer. Other relationships: disclosed
no relevant relationships. M.A.P. disclosed no relevant relationships. J.Y. disclosed
no relevant relationships. J.R.D. Activities related to the present article: institution
received grant from Bracco Diagnostics. Activities not related to the present article:
has grants/grants pending with Canon Medical Solutions, Perspectum Diagnostics, and
Siemens Medical Solutions. Other relationships: disclosed no relevant relationships.
D.F. disclosed no relevant relationships. R.J.M. Activities related to the present article:
author is scientific advisor for GE Healthcare; institution received research funding
from GE Healthcare. Activities not related to the present article: disclosed no relevant
relationships. Other relationships: disclosed no relevant relationships. R.A.R. disclosed no relevant relationships. C.L.W. disclosed no relevant relationships. J.C.W.
Activities related to the present article: received a consulting fee or honorarium
from Bayer Healthcare and Bracco Diagnostics. Activities not related to the present
article: received payment from Ascelia Pharma for research. Other relationships:
disclosed no relevant relationships.

References

1. Davenport MS, Cohan RH, Ellis JH. Contrast media controversies in 2015:
imaging patients with renal impairment or risk of contrast reaction. AJR Am
J Roentgenol 2015;204(6):1174–1181.
2. Davenport MS, Cohan RH, Khalatbari S, Ellis JH. The challenges in assessing
contrast-induced nephropathy: where are we now? AJR Am J Roentgenol
2014;202(4):784–789.
3. Katzberg RW, Newhouse JH. Intravenous contrast medium-induced
nephrotoxicity: is the medical risk really as great as we have come to believe?
Radiology 2010;256(1):21–28.

radiology.rsna.org n Radiology: Volume 294: Number 3—March 2020

Davenport et al
4. Ehrmann S, Aronson D, Hinson JS. Contrast-associated acute kidney injury
is a myth: Yes. Intensive Care Med 2018;44(1):104–106.
5. Weisbord SD, du Cheryon D. Contrast-associated acute kidney injury is a
myth: No. Intensive Care Med 2018;44(1):107–109.
6. Kashani K, Levin A, Schetz M. Contrast-associated acute kidney injury is a
myth: We are not sure. Intensive Care Med 2018;44(1):110–114.
7. Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH.
Contrast material-induced nephrotoxicity and intravenous low-osmolality
iodinated contrast material. Radiology 2013;267(1):94–105.
8. Davenport MS, Khalatbari S, Cohan RH, Dillman JR, Myles JD, Ellis JH.
Contrast material-induced nephrotoxicity and intravenous low-osmolality
iodinated contrast material: risk stratification by using estimated glomerular
filtration rate. Radiology 2013;268(3):719–728.
9. McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney
injury following intravenous contrast medium administration: a systematic
review and meta-analysis. Radiology 2013;267(1):119–128.
10. McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast materialinduced nephropathy: causal or coincident phenomenon? Radiology
2013;267(1):106–118.
11. McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF,
Williamson EE. Risk of intravenous contrast material-mediated acute kidney
injury: a propensity score-matched study stratified by baseline-estimated
glomerular filtration rate. Radiology 2014;271(1):65–73.
12. Newhouse JH, RoyChoudhury A. Quantitating contrast medium-induced
nephropathy: controlling the controls. Radiology 2013;267(1):4–8.
13. Dekkers IA, van der Molen AJ. Propensity score matching as a substitute for
randomized controlled trials on acute kidney injury after contrast media administration: a systematic review. AJR Am J Roentgenol 2018;211(4):822–826.
14. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the
question: understanding time lags in translational research. J R Soc Med
2011;104(12):510–520.
15. American College of Radiology. Manual on contrast media. Version 10.3.
Reston, Va: American College of Radiology, 2018. https://www.acr.org/
Clinical-Resources/Contrast-Manual. Accessed May 16, 2019.
16. Nyman U, Ahlkvist J, Aspelin P, et al. Preventing contrast medium-induced
acute kidney injury : Side-by-side comparison of Swedish-ESUR guidelines.
Eur Radiol 2018;28(12):5384–5395.
17. Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the
2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney
Dis 2013;61(5):649–672.
18. The Royal College of Radiologists. Standards for intravascular contrast
administration to adult patients. 3rd ed. London, England: The Royal
College of Radiologists, 2015.
19. Schönenberger E, Martus P, Bosserdt M, et al. Kidney injury after intravenous
versus intra-arterial contrast agent in patients suspected of having coronary
artery disease: a randomized trial. Radiology 2019;292(3):664–672.
20. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration
of contrast material: a critical literature analysis. Radiology 2006;239(2):
392–397.
21. Section 2: AKI definition. Kidney Int Suppl (2011) 2012;2(1):19–36.
22. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care
2007;11(2):R31.
23. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012
KDIGO clinical practice guideline for the evaluation and management of
CKD. Am J Kidney Dis 2014;63(5):713–735.
24. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind
the scenes, need for guidance, and a framework for moving forward. Kidney
Int 2014;85(1):49–61.
25. Levey AS. Measurement of renal function in chronic renal disease. Kidney
Int 1990;38(1):167–184.
26. Faucon AL, Bobrie G, Clément O. Nephrotoxicity of iodinated contrast
media: From pathophysiology to prevention strategies. Eur J Radiol
2019;116:231–241.
27. Rosenstock JL, Gilles E, Geller AB, et al. Impact of heart failure on the
incidence of contrast-induced nephropathy in patients with chronic kidney
disease. Int Urol Nephrol 2010;42(4):1049–1054.
28. Stacul F, Bertolotto M, Thomsen HS, et al. Iodine-based contrast media,
multiple myeloma and monoclonal gammopathies: literature review and ESUR
Contrast Media Safety Committee guidelines. Eur Radiol 2018;28(2):683–691.
29. Pahade JK, LeBedis CA, Raptopoulos VD, et al. Incidence of contrastinduced nephropathy in patients with multiple myeloma undergoing
contrast-enhanced CT. AJR Am J Roentgenol 2011;196(5):1094–1101.
30. Crowley MP, Prabhakaran VN, Gilligan OM. Incidence of contrastinduced nephropathy in patients with multiple myeloma undergoing
contrast-enhanced procedures. Pathol Oncol Res 2018;24(4):915–919.

Radiology: Volume 294: Number 3—March 2020 n radiology.rsna.org

31. Eng J, Subramaniam RM, Wilson RF, et al. Contrast-induced nephropathy:
comparative effects of different contrast media. Report No. 15(16)-EHC022EF. Rockville, Md: Agency for Healthcare Research and Quality (US), 2015.
32. Subramaniam RM, Wilson RF, Turban S, et al. Contrast-induced nephropathy: comparative effectiveness of preventive measures. Report No.
15(16)-EHC023-EF. Rockville, Md: Agency for Healthcare Research and
Quality (US), 2016.
33. Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy
with volume expansion. Clin J Am Soc Nephrol 2008;3(1):273–280.
34. Nijssen EC, Nelemans PJ, Rennenberg RJ, Theunissen RA, van Ommen V,
Wildberger JE. Prophylaxis in High-Risk Patients With eGFR , 30 mL/min/
1.73 m2: Get the Balance Right. Invest Radiol 2019;54(9):580–588.
35. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to
protect renal function from intravascular iodinated contrast material in patients
at high risk of contrast-induced nephropathy (AMACING): a prospective,
randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet
2017;389(10076):1312–1322.
36. Ellis JH, Khalatbari S, Yosef M, Cohan RH, Davenport MS. Influence of
clinical factors on risk of contrast-induced nephrotoxicity from IV iodinated
low-osmolality contrast material in patients with a low estimated glomerular
filtration rate. AJR Am J Roentgenol 2019;213(5):W188–W193.
37. van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney
injury. Part 2: risk stratification, role of hydration and other prophylactic
measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee
guidelines. Eur Radiol 2018;28(7):2856–2869.
38. Cheungpasitporn W, Thongprayoon C, Brabec BA, Edmonds PJ, O’Corragain
OA, Erickson SB. Oral hydration for prevention of contrast-induced acute
kidney injury in elective radiological procedures: a systematic review and metaanalysis of randomized controlled trials. N Am J Med Sci 2014;6(12):618–624.
39. Agarwal SK, Mohareb S, Patel A, et al. Systematic oral hydration with
water is similar to parenteral hydration for prevention of contrast-induced
nephropathy: an updated meta-analysis of randomised clinical data. Open
Heart 2015;2(1):e000317.
40. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with
sodium bicarbonate and acetylcysteine. N Engl J Med 2018;378(7):603–614.
41. Davenport MS, Khalatbari S, Cohan RH, Ellis JH. Contrast medium-induced
nephrotoxicity risk assessment in adult inpatients: a comparison of serum
creatinine level- and estimated glomerular filtration rate-based screening
methods. Radiology 2013;269(1):92–100.
42. National Institute of Diabetes and Digestive and Kidney Diseases. Creatinine standardization recommendations. https://www.niddk.nih.gov/
health-information/communication-programs/nkdep/laboratory-evaluation/
glomerular-filtration-rate/creatinine-standardization/recommendations. Accessed May 16, 2019.
43. Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech
Urol 1998;4(2):65–69.
44. Too CW, Ng WY, Tan CC, Mahmood MI, Tay KH. Screening for impaired
renal function in outpatients before iodinated contrast injection: Comparing the Choyke questionnaire with a rapid point-of-care-test. Eur J Radiol
2015;84(7):1227–1231.
45. Pannu N, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Prophylaxis
strategies for contrast-induced nephropathy. JAMA 2006;295(23):2765–
2779.
46. Kawashima S, Takano H, Iino Y, Takayama M, Takano T. Prophylactic hemodialysis does not prevent contrast-induced nephropathy after
cardiac catheterization in patients with chronic renal insufficiency. Circ J
2006;70(5):553–558.
47. Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal
replacement therapies for prevention of radiocontrast-induced nephropathy:
a systematic review. Am J Med 2012;125(1):66–78.e3.
48. McDonald JS, Katzberg RW, McDonald RJ, Williamson EE, Kallmes DF. Is
the presence of a solitary kidney an independent risk factor for acute kidney
injury after contrast-enhanced CT? Radiology 2016;278(1):74–81.
49. Malyszko J, Kozlowska K, Kozlowski L, Malyszko J. Nephrotoxicity of
anticancer treatment. Nephrol Dial Transplant 2017;32(6):924–936.
50. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H. Impact of reninangiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy:
a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol
Dial Transplant 2010;25(3):759–764.
51. Onuigbo MAC, Onuigbo NTC. Does renin-angiotensin aldosterone
system blockade exacerbate contrast-induced nephropathy in patients with
chronic kidney disease? A prospective 50-month Mayo Clinic study. Ren Fail
2008;30(1):67–72.

667

Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease
52. Duan SB, Zhou XR, Peng YM, et al. Prevention of radiocontrast-mediainduced nephrotoxicity by perindopril and amlodipine in humans. China J
Mod Med 2003;13:32–36. http://en.cnki.com.cn/Article_en/CJFDTOTALZXDY200322008.htm.
53. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised
study. Indian Heart J 1999;51(5):521–526.
54. Hashemi M, Kharazi A, Shahidi S. Captopril for prevention of contrastinduced nephropathy in patients undergoing coronary angiography: a
double-blind placebo controlled clinical trial. J Res Med Sci 2005;10(5):
305–308.
55. Shemirani H, Pourrmoghaddas M. A randomized trial of saline hydration
to prevent contrast-induced nephropathy in patients on regular captopril or
furosemide therapy undergoing percutaneous coronary intervention. Saudi
J Kidney Dis Transpl 2012;23(2):280–285.
56. Rim MY, Ro H, Kang WC, et al. The effect of renin-angiotensin-aldosterone
system blockade on contrast-induced acute kidney injury: a propensitymatched study. Am J Kidney Dis 2012;60(4):576–582.

668

57. Jo SH, Lee JM, Park J, Kim HS. The impact of renin-angiotensin-aldosterone
system blockade on contrast-induced nephropathy: a meta-analysis of 12
studies with 4,493 patients. Cardiology 2015;130(1):4–14.
58. United States Food and Drug Administration. FDA revises warnings regarding
use of diabetes medicine metformin in certain patients with reduced kidney
function. https://www.fda.gov/media/96771/download. Released April 8,
2016. Accessed June 4, 2019.
59. Schwartz GJ, Work DF. Measurement and estimation of GFR in children
and adolescents. Clin J Am Soc Nephrol 2009;4(11):1832–1843.
60. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate
GFR in children with CKD. J Am Soc Nephrol 2009;20(3):629–637.
61. Staples A, LeBlond R, Watkins S, Wong C, Brandt J. Validation of the revised
Schwartz estimating equation in a predominantly non-CKD population.
Pediatr Nephrol 2010;25(11):2321–2326.
62. McDonald JS, McDonald RJ, Tran CL, Kolbe AB, Williamson EE, Kallmes
DF. Postcontrast acute kidney injury in pediatric patients: a cohort study.
Am J Kidney Dis 2018;72(6):811–818.

radiology.rsna.org n Radiology: Volume 294: Number 3—March 2020

